Systemic Mastocytosis Pipeline: Insights into Novel Pipeline Therapies, Key Pharma Companies, Growth Prospects, and Future Systemic Mastocytosis Pipeline Landscape

DelveInsight's, "Systemic Mastocytosis Pipeline Insight, 2022," report provides comprehensive insights about 8+ companies and 8+ pipeline drugs in Systemic Mastocytosis pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

In the Systemic Mastocytosis pipeline report, detailed description of the drug is given which includes mechanism of action of the drug, Systemic Mastocytosis clinical trials, NDA approvals (if any), and product development activities comprising the technology, Systemic Mastocytosis collaborations, licensing, mergers and acquisition, funding, designations and other product related details.

Key takeaways from the Systemic Mastocytosis Pipeline Report

• Systemic Mastocytosis Pipeline report offers a comprehensive analysis of 8+ key pharma players and 8+key pipeline therapies.
• The leading Systemic Mastocytosis Companies include AB Sciences, Blueprint Medicines, Patara Pharma, Seagen Inc., GT Biopharma, Deciphera Pharmaceuticals, Novartis Oncology, and others.
• Promising Systemic Mastocytosis pipeline therapies include Avapritinib, RAD001 (Everolimus), PA101, Masitinib, AK002, Brentuximab vedotin, and others.
• The Systemic Mastocytosis Companies and academics are working to assess challenges and seek opportunities that could influence Systemic Mastocytosis R&D. The Systemic Mastocytosis pipeline therapies under development are focused on novel approaches to treat/improve Systemic Mastocytosis.
Recent Developmental Activities in the Systemic Mastocytosis Treatment Landscape
• Masitinib's anti-mast cell properties appear particularly well-adapted to the treatment of indolent systemic mastocytosis. A reduction of mast cell activity is generated via its inhibitory action on wild-type c-Kit, Lyn and Fyn tyrosine kinases. In recognition of the critical need for new treatments, masitinib received orphan drug designation for mastocytosis from both the European Medicine Agency (EMA) and the U.S. Food and Drug Administration (FDA). AB Science initiated a confirmatory phase 3 study, with design optimized based on findings from the first phase 3 study.
• The FDA granted breakthrough therapy designation to AYVAKIT for the treatment of advanced SM, including the subtypes of aggressive SM, SM with an associated hematological neoplasm and mast cell leukemia, and for the treatment of moderate to severe indolent SM. The FDA has accepted a supplemental new drug application for avapritinib for the treatment of advanced SM. The European Medicines Agency has validated a Type II variation marketing authorization application for avapritinib for the treatment of advanced SM.

Request for Sample to know which pharma company is expected to be at the forefront in the coming years, Systemic Mastocytosis Pipeline Outlook Report @ https://www.delveinsight.com/sample-request/systemic-mastocytosis-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr

Systemic Mastocytosis Overview

Systemic mastocytosis (SM) is a form of mastocytosis in which mast cells accumulate in internal tissues and organs such as the liver, spleen, bone marrow, and small intestines. It is typically diagnosed in adults. Signs and symptoms vary based on which parts of the body are affected. Too many mast cells can build up in the skin, liver, spleen, bone marrow or intestines. Less commonly, other organs such as the brain, heart or lungs also may be affected. Signs and symptoms of systemic mastocytosis may include: Flushing, itching or hives, Abdominal pain, diarrhea, nausea or vomiting, Anemia or bleeding disorders, Bone and muscle pain, Enlarged liver, spleen or lymph nodes, Depression, mood changes or problems concentrating. The disorder is usually caused by somatic changes (mutations) in the KIT gene. Diagnosis can include the following studies and should be conducted by a physician with special knowledge of this disorder: Skin and bone marrow biopsies, Measurement of mast cell mediators in blood and urine, Blood count, Liver function studies, and Genetic tests. The objective of treatment is to control the effects of mast cell released mediators by avoidance of dietary and environmental triggers as well as the use of various medications.

Systemic Mastocytosis Emerging Drugs Profile
• Avapritinib: Blueprint Medicines
• Masitinib: AB Sciences

Systemic Mastocytosis Therapeutics Assessment
There are approx. 8+ key companies which are developing the therapies for Systemic Mastocytosis. The companies which have their Systemic Mastocytosis drug candidates in the most advanced stage, i.e. Preregistration include, Blueprint Medicines.

Systemic Mastocytosis Report Assessment
• Systemic Mastocytosis Pipeline Product Profiles
• Systemic Mastocytosis Therapeutic Assessment
• Systemic Mastocytosis Pipeline Assessment
• Inactive drugs assessment
• Unmet Needs

For more information on Systemic Mastocytosis Emerging drugs, visit Systemic Mastocytosis Clinical Trials Analysis Report @ https://www.delveinsight.com/sample-request/systemic-mastocytosis-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr

Scope of the Systemic Mastocytosis Pipeline Report
• Coverage- Global
• Systemic Mastocytosis Companies include AB Sciences, Blueprint Medicines, Patara Pharma, Seagen Inc., GT Biopharma, Deciphera Pharmaceuticals, Novartis Oncology, and others.
• Systemic Mastocytosis Pipeline Therapies include Avapritinib, RAD001 (Everolimus), PA101, Masitinib, AK002, Brentuximab vedotin, and others.
• Systemic Mastocytosis Therapeutics Assessment: Phases, Route of Administration, Molecule Type

Table of content
1. Introduction
2. Systemic Mastocytosis Executive Summary
3. Systemic Mastocytosis: Overview
4. Systemic Mastocytosis Pipeline Therapeutics
5. Systemic Mastocytosis Therapeutic Assessment
6. Systemic Mastocytosis - DelveInsight's Analytical Perspective
7. In-depth Commercial Assessment
8. Systemic Mastocytosis Collaboration Deals
9. Late Stage Products (Preregistration)
10. Avapritinib: Blueprint Medicines
11. Drug profiles in the detailed report…..
12. Mid Stage Products (Phase II)
13. PA101: Patara Pharma
14. Drug profiles in the detailed report…..
15. Early stage products (Phase I)
16. DCC-2618: Deciphera Pharmaceuticals
17. Drug profiles in the detailed report…..
18. Inactive Products
19. Systemic Mastocytosis Key Companies
20. Systemic Mastocytosis Key Products
21. Systemic Mastocytosis- Unmet Needs
22. Systemic Mastocytosis- Market Drivers
23. Systemic Mastocytosis Market Barriers
24. Systemic Mastocytosis- Future Perspectives and Conclusion
25. Systemic Mastocytosis Analyst Views
26. Systemic Mastocytosis Key Companies
27. Appendix

Key Questions
Current Treatment Scenario and Emerging Therapies:
• How many companies are developing Systemic Mastocytosis drugs?
• How many Systemic Mastocytosis drugs are developed by each company?
• How many emerging drugs are in mid-stage, and late-stage of development for the treatment of Systemic Mastocytosis?
• What are the key collaborations (Industry-Industry, Industry-Academia), Mergers and acquisitions, licensing activities related to the Systemic Mastocytosis therapeutics?
• What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies?
• What are the clinical studies going on for Systemic Mastocytosis and their status?
• What are the key designations that have been granted to the emerging drugs?

Discover more about the scope of Systemic Mastocytosis Emerging Drugs Report @ https://www.delveinsight.com/report-store/systemic-mastocytosis-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr

Contact Us
Yash Bhardwaj
info@delveinsight.com

About Us
DelveInsight is a Business Consulting and Market research company, providing expert business solutions for the healthcare domain and offering quintessential advisory services in the areas of R&D, Strategy Formulation, Operations, Competitive Intelligence, Competitive Landscaping, and Mergers & Acquisitions.

This release was published on openPR.